Electro-Acupuncture for Obese Patients With Insulin Resistance
Electro-acupuncture for the Obese Patient With Insulin Resistance: a Randomized Sham-controlled Clinical Trial
1 other identifier
interventional
60
1 country
1
Brief Summary
This clinical trial aims to evaluate the efficacy and safety of electro-acupuncture for obese patients with insulin resistance. 60 participants will be randomized and allocated to either the electro-acupuncture arm or the sham acupuncture arm.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable obesity
Started Oct 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 20, 2024
CompletedFirst Posted
Study publicly available on registry
September 24, 2024
CompletedStudy Start
First participant enrolled
October 10, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 9, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
October 9, 2026
ExpectedApril 9, 2026
April 1, 2026
1.5 years
September 20, 2024
April 6, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
delta HOMA-IR
delta HOMA-IR = (end-of-treatment fasting insulin (ųU/mL)\* end-of-treatment fasting glucose (mmol/L)/22.5) - (baseline fasting insulin (ųU/mL)\* baseline fasting glucose (mmol/L)/22.5)
From baseline to the end of treatment at week 8
Secondary Outcomes (2)
Body Mass Index (BMI)
From enrollment to the end of follow-up at week 16
Waist-to-hip ratio
From baseline to the end of follow-up at week 16
Study Arms (2)
Electroacupuncture group
EXPERIMENTALThe WHO Standardized Acupuncture Points Location \[2\] will be used to identify the location of these acupoints, Tianshu(ST-25), Daheng(SP-15), Daimai(GB-24), Qihai(CV-6), Zhongwan(CV-12), Zusanli (ST-36), Fenlong(ST-40), and Sanyinjiao(SP-6). After sterilizing the skin, sterile adhesive pads will be pasted on acupoints first, and then needles of size 0.30\*75 mm will be inserted into the acupoints to a depth of 50 mm outward and upward slightly. Needles will be lifted, thrust, and twirled evenly 3 times to achieve "de-qi". Paired electrodes of the EA apparatus will be attached transversely to the acupoint respectively with a continuous wave of 50 Hz and a current intensity of 1-5 mA (preferably with the skin around the acupoints shivering mildly without pain) for 30 min. Patients will be treated with electroacupuncture 2 sessions per week over 8 consecutive weeks, 16 sessions for each patient.
Sham acupuncture group
SHAM COMPARATORThe sham electro-acupuncture group (SEA) penetrates acupuncture on non-acupuncture points (1 cm away from the acupuncture point and meridian). The same type of acupuncture needles will be used for SEA with the exact skin sterilization method. All acupuncture points will be needled perpendicularly with a guide tube. Insertion depth will be approximately 50 mm, depending on the location of individual points. Each point will be connected to a sham electro-stimulator (showing a continuous wave at a frequency of 30 Hz but without actual stimulation). All needles will be removed after 30 min of needle retention. Patients will be treated with sham electroacupuncture 2 sessions per week over 8 consecutive weeks, 16 sessions for each patient in total.
Interventions
The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.
Eligibility Criteria
You may qualify if:
- Men and women aged between 21 and 65 years old
- BMI ≥ 25 kg/m2
- HOMA-IR ≥ 2.14, (HOMA-IR = fasting insulin (ųU/mL)\* fasting glucose (mmol/L)/22.5)
- Not receiving any other weight control measures or any medical and/or drug history in the last 3 months
You may not qualify if:
- Diabetes mellitus
- Treating with drugs that may affect insulin sensitivity
- Changes 10% of usual body weight in the previous 6 months weight
- Endocrine diseases, including thyroid disorder, pituitary disorder, sex gland disorder, etc.
- Heart diseases, including arrhythmia, heart failure, and myocardial infarction, participants with pacemakers
- Allergy and immunology diseases
- Bleeding tendency
- Pregnant or lactating women
- Impaired hepatic or renal function
- Stroke or unable to exercise
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Nanyang Technological University Traditional Chinese Medicine Clinic
Singapore, 637551, Singapore
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Linda Zhong, Ph.D.
nanyang technological university traditional chinese medicine clinic
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Masking Details
- After a participant's eligibility is confirmed, a randomization number that corresponds to the group allocation will be provided to the acupuncturist. The clinical assessor and participants will be blinded to the allocation.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assoc prof
Study Record Dates
First Submitted
September 20, 2024
First Posted
September 24, 2024
Study Start
October 10, 2024
Primary Completion
April 9, 2026
Study Completion (Estimated)
October 9, 2026
Last Updated
April 9, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
- Time Frame
- Data will become available within 7 years after completion of the clinical trial.
- Access Criteria
- Individual participant data (IPD) will be made available to qualified researchers upon request. To access the data, researchers must submit a formal request, which will be reviewed and approved by the data-sharing committee. Data access will be granted for research purposes only and will require adherence to data use agreements and ethics guidelines.
IPD sharing will be available upon request.